NCT01243983 - Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Noninfectious Uveitis

Interventions

DRUG

LX211

"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"

Trial Locations (52)

1030

Vienna

12808

Prague

19107

Philadelphia

20132

Milan

21287

Baltimore

23219

Richmond

23502

Norfolk

27157

Winston-Salem

28012

Belmont

29456

Ladson

33000

Bordeaux

35128

Padua

40138

Bologna

42100

Reggio Emilia

43016

Dublin

43126

Parma

44122

Cleveland

44130

Middleburg Heights

44195

Cleveland

46290

Indianapolis

48145

Münster

49933

Angers

50005

Hradec Králové

62500

Brno

72076

Tübingen

72205

Little Rock

75013

Paris

75019

Paris

75231

Dallas

76012

Arlington

77030

Houston

77520

Olomouc

78240

San Antonio

85014

Phoenix

85381

Peoria

90211

Beverly Hills

90503

Torrance

92705

Santa Ana

94040

Mountain View

95819

Sacramento

97520

Ashland

04605

Ellsworth

02142

Cambridge

07103

Newark

50070-040, PE

Recife

21941-913, RJ

Rio de Janeiro

04023-062, SP

São Paulo

K1H 8L6

Ottawa

B18 7QU

Birmingham

EC1V 2PD

London

SE1 7EH

London

YO31 8HE

York